Rigorous Assessment of P. vivax Relapses and Primaquine Efficacy for Radical Cure

间日疟原虫威胁着世界上一半的人口。虽然正在进行的消灭疟疾的努力是 虽然成功地减少了全球恶性疟疾的负担，但P. 间日疟原虫特别是间日疟原虫在肝脏中保持休眠并导致复发的独特能力 感染数周或数月后，疟疾消除运动变得非常复杂。在这里，我们建议进行 在柬埔寨进行严格控制的实地研究，专门用于支持和授权最先进的 基因组分析，以确定复发的频率和与催眠子再激活相关的因素， 以及严格评估不同剂量伯氨喹用于根治治疗的功效。我们 研究将为间日疟原虫复发提供一个独特的视角，并将有助于更好地了解如何 成功地消灭了这种未被充分研究的寄生虫

Plasmodium vivax threatens half of the world’s population. While on-going malaria elimination efforts are successfully reducing the burden of falciparum malaria worldwide, the situation is much less promising for P. vivax. In particular, the unique ability of P. vivax parasites to remain dormant in the liver and cause relapse infections weeks or months later greatly complicates malaria elimination campaigns. Here we propose to conduct a tightly-controlled field study in Cambodia, specifically designed to support and empower state-of-the-art genomic analyses, to determine the frequency of relapse and the factors associated with hypnozoite reactivation, as well as to rigorously evaluate the efficacy of different doses of primaquine for radical cure treatment. Our studies will provide a unique perspective on P. vivax relapse and will contribute to better understand how to successfully eliminate this understudied parasite.